Programs that are staffed by specialists who provide comprehensive treatment services for individuals with moderate to severe symptoms for COVID-19, who are at risk of progressing to severe illness and hospitalization. The spectrum of medical therapies to treat COVID-19 is growing and evolving rapidly, including both drugs approved by U.S. Food and Drug Administration (FDA) and drugs made available under FDA emergency use authorization (EUA). Current clinical management of COVID-19 consists of infection prevention and control measures and supportive care, including supplemental oxygen and mechanical ventilatory support when indicated. The FDA has approved one drug, remdesivir (Veklury), for the treatment of COVID-19 in certain situations, and a number of novel therapeutics (e.g., monoclonal antibodies) are available under EUA for early outpatient treatment.